Amid new government directives around diversity, equity, and inclusion programs in the US, our April issue explores the pivots and adjustments pharma and healthcare interests are making to maintain the progress of such efforts in advancing clinical research.
Related Posts
Eli Lilly’s Oral GLP-1, Orforglipron, Demonstrates Efficacy and Safety Consistent with Injectable GLP-1s in Phase III Trial
Image Credit: © Mnt – stock.adobe.com Eli Lilly has shared positive Phase III clinical trial data of its investigational, oral…
Navigating Evolving DEI Measures in Clinical Patient Recruitment: A Deep Dive
Image credit: Dzmitry | stock.adobe.com. Embarking on a journey through the ever-evolving landscape of clinical patient recruitment, it is important…
Industry Leaders Discuss the Impact of FDA’s Diversity Action Plan
Tenaerts: I think it’ll help the industry get more data, actionable data on a diverse population—there’s different ways to do…